Sixteen years from question to comeback.
Sofusa was born inside one of the world's great manufacturing companies, proven in the clinic by a global pharma — and brought back to life to finish the job.
An idea takes shape
Founded at Kimberly-Clark, where the complete design and manufacturing concept for the lymphatic delivery device came together — and early proof of concept showed the device worked.
A bigger stage
Sorrento Therapeutics acquired the Sofusa platform from Kimberly-Clark, then ran it through clinical trials in autoimmune disease and oncology.
The roadblock
Sorrento Therapeutics files for Chapter 11 — and the Sofusa platform's future hangs in the balance.
Proof — and rebirth
Clinical studies delivered proof of concept. And after Sorrento's bankruptcy, Sofusa was brought back to life as an independent company.
Bringing it to market Now
Sofusa Holdings is working to bring precision lymphatic medicine to patients — empowering the lymphatics to transform biologic therapy.